The “Futurology” of Biopharma

Deepak Singh writes about a report commissioned by British Telecom, which examines the future of the biopharma industry. The core argument of the report, writes Singh at business|bytes|genes|molecules, is that the industry needs to change “by becoming one part of the healthcare ecosystem, one driven by communication technologies and the increased digitization of patient information.” He tackles some key features of the report, called “Pharma Futurology: Joined-up healthcare, 2016 and beyond,” including whether drug development based on in silico models is really only a decade away, the need for physicians to redefine their roles, and in what form personalized medicine will actually materialize.